piroxicam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anti-inflammatory, isoxicam derivatives	2210	36322-90-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: piroxicam olamine piroxicam betadex brexicam brexidol brexin cicladol piroxicam-beta-cyclodextrin complex piroxicam beta-cyclodextrin feldene CP16171 CP-16171 piroxicam	A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. Molecular weight: 331.35 Formula: C15H13N3O4S CLOGP: 1.89 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 99.60 ALOGS: -3.37 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

piroxicam olamine
piroxicam betadex
brexicam
brexidol
brexin
cicladol
piroxicam-beta-cyclodextrin complex
piroxicam beta-cyclodextrin
feldene
CP16171
CP-16171
piroxicam

A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.

Molecular weight: 331.35
Formula: C15H13N3O4S
CLOGP: 1.89
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 99.60
ALOGS: -3.37
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O
20	mg	P
20	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.51 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 6, 1982	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sciatica	657.97	15.07	306	25201	34018	63429497
Drug hypersensitivity	422.91	15.07	569	24938	310118	63153397
Psoriatic arthropathy	406.38	15.07	318	25189	91202	63372313
Sinusitis	189.69	15.07	332	25175	226321	63237194
Blood iron abnormal	182.93	15.07	66	25441	3810	63459705
Treatment failure	145.39	15.07	275	25232	198768	63264747
Deep vein thrombosis postoperative	145.18	15.07	77	25430	11292	63452223
Rheumatoid arthritis	140.88	15.07	313	25194	253506	63210009
Drug intolerance	124.82	15.07	337	25170	308324	63155191
Autoimmune disorder	118.15	15.07	78	25429	17099	63446416
Rheumatic fever	114.56	15.07	112	25395	42999	63420516
Swollen joint count increased	111.73	15.07	102	25405	35952	63427563
Prescribed overdose	100.74	15.07	94	25413	34059	63429456
Therapeutic product effect incomplete	98.99	15.07	179	25328	124877	63338638
Condition aggravated	98.97	15.07	370	25137	401847	63061668
C-reactive protein abnormal	90.69	15.07	102	25405	45994	63417521
Hallucinations, mixed	86.06	15.07	41	25466	4788	63458727
Fibromyalgia	84.88	15.07	131	25376	80289	63383226
Liver injury	83.54	15.07	112	25395	60408	63403107
Lip dry	80.05	15.07	59	25448	15411	63448104
Multiple allergies	76.79	15.07	55	25452	13747	63449768
Blood cholesterol increased	76.17	15.07	136	25371	93896	63369619
Death	75.63	15.07	28	25479	374353	63089162
Adjustment disorder with depressed mood	74.23	15.07	48	25459	10156	63453359
C-reactive protein	73.67	15.07	37	25470	4845	63458670
Rheumatic disorder	73.42	15.07	32	25475	3040	63460475
Duodenal ulcer perforation	70.47	15.07	126	25381	87083	63376432
Injury	68.60	15.07	113	25394	73134	63390381
Type 2 diabetes mellitus	67.33	15.07	104	25403	63764	63399751
Thermal burn	66.22	15.07	37	25470	6009	63457506
X-ray abnormal	63.59	15.07	40	25467	8070	63455445
Red blood cell sedimentation rate increased	61.61	15.07	82	25425	43900	63419615
Oedema	61.60	15.07	127	25380	97495	63366020
Mobility decreased	61.04	15.07	144	25363	121015	63342500
Laryngeal disorder	57.76	15.07	20	25487	1022	63462493
Adverse reaction	57.54	15.07	41	25466	10162	63453353
Musculoskeletal pain	55.82	15.07	118	25389	92159	63371356
Pneumonia	55.62	15.07	61	25446	456706	63006809
Rash	55.49	15.07	400	25107	560471	62903044
Gait inability	55.48	15.07	86	25421	52873	63410642
Intestinal diaphragm disease	49.73	15.07	11	25496	99	63463416
Bursitis	48.74	15.07	67	25440	36974	63426541
Peripheral venous disease	48.34	15.07	44	25463	15433	63448082
Obesity	46.88	15.07	59	25448	29893	63433622
Adverse event	46.31	15.07	91	25416	67468	63396047
Live birth	45.82	15.07	54	25453	25576	63437939
Hypoaesthesia	45.55	15.07	160	25347	168233	63295282
Facet joint syndrome	44.92	15.07	38	25469	12100	63451415
Lower limb fracture	44.92	15.07	52	25455	24169	63439346
Blood immunoglobulin M increased	44.86	15.07	17	25490	1126	63462389
Contraindicated product administered	44.32	15.07	189	25318	217459	63246056
Prescribed underdose	44.13	15.07	57	25450	29632	63433883
Wound infection	43.16	15.07	48	25459	21362	63442153
Blood immunoglobulin A decreased	42.52	15.07	17	25490	1300	63462215
Wound	42.33	15.07	153	25354	163110	63300405
Dry mouth	41.89	15.07	95	25412	77768	63385747
Product dose omission issue	41.74	15.07	21	25486	234292	63229223
Grip strength decreased	41.58	15.07	48	25459	22239	63441276
Helicobacter infection	41.10	15.07	105	25402	92680	63370835
Therapeutic product effect decreased	40.29	15.07	169	25338	193018	63270497
Wheezing	40.11	15.07	106	25401	95489	63368026
Blister	40.10	15.07	129	25378	129685	63333830
Breast cancer stage II	40.06	15.07	31	25476	8705	63454810
Hallucination, auditory	39.16	15.07	36	25471	12788	63450727
Rheumatoid factor positive	35.82	15.07	94	25413	84312	63379203
Dyspnoea	35.03	15.07	142	25365	661171	62802344
Road traffic accident	34.93	15.07	57	25450	36575	63426940
Folliculitis	34.76	15.07	83	25424	70234	63393281
Cough	34.59	15.07	40	25467	292703	63170812
Memory impairment	34.39	15.07	106	25401	104152	63359363
Musculoskeletal stiffness	34.29	15.07	156	25351	184462	63279053
Product use issue	34.25	15.07	177	25330	220343	63243172
Dislocation of vertebra	33.95	15.07	28	25479	8607	63454908
Acute kidney injury	33.32	15.07	34	25473	263381	63200134
Blood immunoglobulin G increased	32.57	15.07	17	25490	2410	63461105
Osteoarthritis	31.50	15.07	97	25410	95246	63368269
Febrile neutropenia	31.36	15.07	5	25502	118444	63345071
Fall	30.95	15.07	70	25437	392264	63071251
Fixed eruption	30.70	15.07	13	25494	1151	63462364
Night sweats	30.17	15.07	63	25444	48751	63414764
Dehydration	30.17	15.07	16	25491	173338	63290177
Arthropathy	30.14	15.07	179	25328	234613	63228902
Anti-cyclic citrullinated peptide antibody positive	29.34	15.07	108	25399	116104	63347411
Discomfort	29.28	15.07	139	25368	167235	63296280
Neutropenia	29.23	15.07	17	25490	174988	63288527
Pericarditis	28.11	15.07	116	25391	131463	63332052
Colitis microscopic	28.09	15.07	26	25481	9313	63454202
Hip arthroplasty	27.72	15.07	60	25447	47586	63415929
Hypotension	27.36	15.07	42	25465	272562	63190953
Adverse drug reaction	27.17	15.07	82	25425	79632	63383883
Anaemia	26.85	15.07	48	25459	293382	63170133
Neurosis	26.57	15.07	8	25499	260	63463255
Completed suicide	26.01	15.07	13	25494	145660	63317855
COVID-19	25.38	15.07	7	25500	113096	63350419
Tri-iodothyronine free decreased	25.08	15.07	8	25499	316	63463199
Muscle injury	24.94	15.07	70	25437	65275	63398240
Arrhythmogenic right ventricular dysplasia	24.83	15.07	5	25502	27	63463488
Joint swelling	24.78	15.07	220	25287	327446	63136069
Knee arthroplasty	24.68	15.07	62	25445	54144	63409371
Sepsis	24.01	15.07	16	25491	153107	63310408
Treatment noncompliance	22.86	15.07	48	25459	37277	63426238
Joint range of motion decreased	22.60	15.07	44	25463	32384	63431131
Delirium	22.17	15.07	57	25450	50484	63413031
Lung disorder	22.12	15.07	65	25442	62196	63401319
Sleep disorder due to general medical condition, insomnia type	21.99	15.07	58	25449	52159	63411356
Seizure	21.98	15.07	13	25494	132621	63330894
Cataract operation	21.91	15.07	18	25489	5504	63458011
Infusion site scar	21.31	15.07	8	25499	516	63462999
Quadriparesis	21.09	15.07	12	25495	2017	63461498
Urinary tract infection	21.03	15.07	47	25460	264637	63198878
Malignant neoplasm progression	20.57	15.07	4	25503	82117	63381398
Synovitis	20.54	15.07	137	25370	186781	63276734
Pleural effusion	20.48	15.07	6	25501	93204	63370311
Cross sensitivity reaction	20.38	15.07	12	25495	2150	63461365
Decreased appetite	20.23	15.07	171	25336	250881	63212634
Gastrointestinal disorder	20.11	15.07	105	25402	131134	63332381
Liver disorder	19.99	15.07	57	25450	53630	63409885
Pulmonary fibrosis	19.68	15.07	47	25460	39762	63423753
Hepatic enzyme abnormal	19.62	15.07	18	25489	6374	63457141
Peritoneal haematoma	19.11	15.07	5	25502	96	63463419
Persistent depressive disorder	18.97	15.07	9	25498	1041	63462474
Intentional product use issue	18.69	15.07	101	25406	127791	63335724
Hernia	18.46	15.07	24	25483	12550	63450965
Drug-induced liver injury	18.30	15.07	46	25461	40176	63423339
Fatigue	17.73	15.07	251	25256	887777	62575738
Duodenal polyp	17.49	15.07	5	25502	135	63463380
Constipation	17.02	15.07	41	25466	224902	63238613
Basophil count increased	16.67	15.07	8	25499	949	63462566
Thrombosis	16.55	15.07	3	25504	64752	63398763
Thrombocytopenia	16.42	15.07	22	25485	151135	63312380
Irritable bowel syndrome	16.30	15.07	71	25436	82341	63381174
Abdominal pain upper	16.30	15.07	140	25367	206304	63257211
Intentional overdose	15.88	15.07	5	25502	74147	63389368
Impaired healing	15.68	15.07	82	25425	102460	63361055
Oxygen saturation decreased	15.66	15.07	8	25499	88577	63374938
Respiratory failure	15.49	15.07	11	25496	101847	63361668
Uveitis	15.46	15.07	22	25485	12531	63450984
Skin reaction	15.38	15.07	24	25483	14825	63448690
Influenza like illness	15.24	15.07	4	25503	66820	63396695
Amnesia	15.16	15.07	53	25454	55532	63407983
Ear pain	15.08	15.07	40	25467	36078	63427437

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	53.59	15.94	60	4662	80469	34871740
Sacroiliitis	49.81	15.94	15	4707	1483	34950726
Mast cell activation syndrome	46.95	15.94	10	4712	240	34951969
Fixed eruption	39.72	15.94	13	4709	1687	34950522
Chest expansion decreased	39.59	15.94	8	4714	147	34952062
Osteopenia	39.04	15.94	17	4705	4832	34947377
Benign abdominal neoplasm	37.06	15.94	7	4715	89	34952120
Angioedema	34.09	15.94	33	4689	37341	34914868
Ankylosing spondylitis	33.60	15.94	16	4706	5588	34946621
Urticaria	32.41	15.94	41	4681	62336	34889873
Duodenal ulcer	32.04	15.94	19	4703	10313	34941896
Spondylitis	30.78	15.94	10	4712	1268	34950941
Acute generalised exanthematous pustulosis	30.72	15.94	16	4706	6760	34945449
Enthesopathy	30.21	15.94	14	4708	4599	34947610
Joint range of motion decreased	29.57	15.94	16	4706	7296	34944913
Axial spondyloarthritis	28.00	15.94	7	4715	345	34951864
Cross sensitivity reaction	25.98	15.94	9	4713	1388	34950821
Death	25.51	15.94	11	4711	398038	34554171
Polychondritis	25.12	15.94	6	4716	244	34951965
Oral pruritus	23.68	15.94	6	4716	312	34951897
Brain hypoxia	23.08	15.94	6	4716	346	34951863
Adrenoleukodystrophy	20.09	15.94	4	4718	68	34952141
Drug interaction	19.64	15.94	71	4651	225875	34726334
Vitreous haemorrhage	18.06	15.94	8	4714	2365	34949844
Antisocial behaviour	17.61	15.94	5	4717	402	34951807
Suicidal ideation	17.05	15.94	24	4698	40364	34911845
Inflammatory bowel disease	16.48	15.94	8	4714	2912	34949297
Spinal cord infection	16.44	15.94	4	4718	176	34952033
Anaphylactic reaction	16.39	15.94	21	4701	32280	34919929
Adulterated product	16.36	15.94	3	4719	32	34952177

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sciatica	534.56	15.56	248	26397	32974	79684769
Psoriatic arthropathy	372.09	15.56	263	26382	77736	79640007
Drug hypersensitivity	355.72	15.56	467	26178	298449	79419294
Sinusitis	189.34	15.56	277	26368	195224	79522519
Rheumatoid arthritis	168.96	15.56	272	26373	208198	79509545
Rheumatic fever	166.33	15.56	109	26536	28416	79689327
Swollen joint count increased	162.16	15.56	99	26546	22828	79694915
Treatment failure	158.45	15.56	237	26408	170249	79547494
Deep vein thrombosis postoperative	153.55	15.56	74	26571	10678	79707065
Blood iron abnormal	152.92	15.56	43	26602	1324	79716419
Drug intolerance	135.74	15.56	283	26362	263836	79453907
Autoimmune disorder	125.91	15.56	75	26570	16537	79701206
Duodenal ulcer perforation	119.03	15.56	128	26517	66083	79651660
Fibromyalgia	116.74	15.56	125	26520	64215	79653528
Blood cholesterol increased	108.85	15.56	137	26508	83583	79634160
Prescribed overdose	103.26	15.56	92	26553	37791	79679952
Liver injury	100.96	15.56	109	26536	56505	79661238
Multiple allergies	100.13	15.56	55	26590	10405	79707338
C-reactive protein abnormal	98.55	15.56	100	26545	48267	79669476
Death	97.37	15.56	34	26611	566480	79151263
Type 2 diabetes mellitus	89.85	15.56	103	26542	57019	79660724
Contraindicated product administered	89.36	15.56	176	26469	157362	79560381
Adjustment disorder with depressed mood	84.84	15.56	47	26598	9039	79708704
Lip dry	80.44	15.56	55	26590	15363	79702380
X-ray abnormal	79.96	15.56	39	26606	5774	79711969
Injury	79.53	15.56	113	26532	77383	79640360
C-reactive protein	79.46	15.56	37	26608	4942	79712801
Rheumatic disorder	78.26	15.56	32	26613	3126	79714617
Mobility decreased	76.03	15.56	142	26503	122033	79595710
Helicobacter infection	75.03	15.56	104	26541	69600	79648143
Pneumonia	74.21	15.56	67	26578	660179	79057564
Arthropathy	70.93	15.56	172	26473	176939	79540804
Discomfort	70.80	15.56	140	26505	125477	79592266
Therapeutic product effect incomplete	67.12	15.56	147	26498	141498	79576245
Rheumatoid factor positive	66.99	15.56	91	26554	59748	79657995
Live birth	66.49	15.56	53	26592	18691	79699052
Blister	64.75	15.56	131	26514	119345	79598398
Therapeutic product effect decreased	64.40	15.56	158	26487	163705	79554038
Oedema	63.48	15.56	130	26515	119450	79598293
Anti-cyclic citrullinated peptide antibody positive	61.18	15.56	104	26541	83039	79634704
Condition aggravated	60.47	15.56	328	26317	500796	79216947
Hypoaesthesia	60.23	15.56	163	26482	179189	79538554
Wound	60.13	15.56	125	26520	116054	79601689
Musculoskeletal stiffness	59.72	15.56	160	26485	174848	79542895
Rash	59.64	15.56	363	26282	577995	79139748
Gait inability	59.10	15.56	85	26560	58832	79658911
Folliculitis	57.17	15.56	81	26564	55299	79662444
Musculoskeletal pain	56.37	15.56	113	26532	102241	79615502
Pericarditis	56.12	15.56	114	26531	104122	79613621
Joint swelling	54.88	15.56	216	26429	288430	79429313
Peripheral venous disease	54.34	15.56	44	26601	15865	79701878
Acute kidney injury	53.34	15.56	57	26588	519347	79198396
Bursitis	51.96	15.56	62	26583	35782	79681961
Lower limb fracture	50.96	15.56	50	26595	23165	79694578
Product use issue	50.88	15.56	170	26475	209652	79508091
Fixed eruption	50.41	15.56	23	26622	2931	79714812
Pemphigus	50.19	15.56	106	26539	99476	79618267
Neutropenia	49.80	15.56	17	26628	287693	79430050
Hypotension	49.01	15.56	45	26600	440272	79277471
Facet joint syndrome	48.97	15.56	36	26609	11266	79706477
Adverse event	47.88	15.56	78	26567	60136	79657607
Grip strength decreased	47.82	15.56	47	26598	21822	79695921
Prescribed underdose	47.72	15.56	54	26591	29460	79688283
Wound infection	45.95	15.56	48	26597	23943	79693800
Joint range of motion decreased	45.69	15.56	56	26589	33226	79684517
Synovitis	45.67	15.56	132	26513	150602	79567141
Blood immunoglobulin M increased	44.96	15.56	17	26628	1349	79716394
Breast cancer stage II	44.82	15.56	30	26615	8090	79709653
Blood immunoglobulin A decreased	43.94	15.56	17	26628	1436	79716307
Dry mouth	43.55	15.56	93	26552	87926	79629817
Swelling	43.47	15.56	165	26480	216546	79501197
Sepsis	43.15	15.56	18	26627	269410	79448333
Glossodynia	43.10	15.56	102	26543	103235	79614508
Febrile neutropenia	42.93	15.56	12	26633	230987	79486756
Hand deformity	42.72	15.56	102	26543	103817	79613926
Muscle injury	41.48	15.56	65	26580	48496	79669247
Laryngeal disorder	41.06	15.56	15	26630	1081	79716662
Systemic lupus erythematosus	39.54	15.56	109	26536	121040	79596703
Hip arthroplasty	39.44	15.56	54	26591	35702	79682041
Intestinal diaphragm disease	39.10	15.56	11	26634	339	79717404
Adverse reaction	38.85	15.56	29	26616	9285	79708458
Adverse drug reaction	38.60	15.56	75	26570	66317	79651426
Red blood cell sedimentation rate increased	38.55	15.56	61	26584	45881	79671862
Osteoarthritis	38.40	15.56	88	26557	87221	79630522
Wheezing	38.11	15.56	105	26540	116559	79601184
Blood immunoglobulin G increased	37.97	15.56	19	26626	2970	79714773
Road traffic accident	36.67	15.56	58	26587	43606	79674137
Dislocation of vertebra	36.18	15.56	26	26619	7854	79709889
Obesity	35.69	15.56	51	26594	35074	79682669
Anaemia	34.39	15.56	60	26585	444955	79272788
Knee arthroplasty	34.34	15.56	56	26589	43192	79674551
Maternal exposure during pregnancy	33.40	15.56	111	26534	136427	79581316
Night sweats	32.94	15.56	61	26584	52034	79665709
Sleep disorder due to general medical condition, insomnia type	32.71	15.56	55	26590	43501	79674242
Respiratory failure	32.50	15.56	10	26635	180901	79536842
Product dose omission issue	31.64	15.56	22	26623	247515	79470228
Fall	31.48	15.56	73	26572	487556	79230187
Cross sensitivity reaction	31.40	15.56	18	26627	3694	79714049
Gastrointestinal disorder	31.37	15.56	101	26544	122104	79595639
Sacroiliitis	31.21	15.56	18	26627	3736	79714007
Irritable bowel syndrome	31.06	15.56	66	26579	62175	79655568
Thrombocytopenia	30.82	15.56	26	26619	265233	79452510
Toxicity to various agents	30.64	15.56	59	26586	421481	79296262
Chest expansion decreased	30.55	15.56	8	26637	187	79717556
Malignant neoplasm progression	29.43	15.56	5	26640	135985	79581758
Contusion	28.76	15.56	112	26533	148664	79569079
Cough	27.83	15.56	50	26595	366739	79351004
Urticaria	27.73	15.56	129	26516	185072	79532671
Colitis microscopic	27.07	15.56	25	26620	10743	79707000
Dehydration	26.83	15.56	26	26619	248161	79469582
Cataract operation	25.87	15.56	18	26627	5167	79712576
Impaired healing	25.80	15.56	76	26569	87579	79630164
Infusion site scar	25.64	15.56	8	26637	355	79717388
Ill-defined disorder	25.29	15.56	63	26582	65812	79651931
Tri-iodothyronine free decreased	25.27	15.56	8	26637	372	79717371
Arrhythmogenic right ventricular dysplasia	25.16	15.56	5	26640	31	79717712
Spondylitis	24.97	15.56	17	26628	4714	79713029
COVID-19	24.49	15.56	11	26634	157663	79560080
Neurosis	24.18	15.56	8	26637	429	79717314
Ear pain	24.01	15.56	41	26604	32828	79684915
Seizure	23.84	15.56	17	26628	188817	79528926
Benign abdominal neoplasm	23.15	15.56	7	26638	279	79717464
Pleural effusion	22.77	15.56	10	26635	145252	79572491
Abdominal pain upper	22.65	15.56	140	26505	223679	79494064
Lupus vulgaris	22.51	15.56	14	26631	3332	79714411
Hernia	22.28	15.56	28	26617	17031	79700712
Arthralgia	22.26	15.56	290	26355	571513	79146230
Alopecia	21.73	15.56	142	26503	231213	79486530
Duodenal ulcer	21.59	15.56	27	26618	16342	79701401
Drug abuse	21.40	15.56	14	26631	162677	79555066
Neutrophil count decreased	21.37	15.56	3	26642	93956	79623787
Hepatic enzyme abnormal	21.34	15.56	19	26626	7791	79709952
Atrial fibrillation	21.07	15.56	21	26624	197865	79519878
Pulmonary embolism	20.96	15.56	16	26629	171638	79546105
Dyspnoea	20.73	15.56	185	26460	856840	78860903
Hypersensitivity	19.99	15.56	153	26492	262086	79455657
Pulmonary fibrosis	19.98	15.56	45	26600	44067	79673676
Dyspepsia	19.53	15.56	80	26565	108607	79609136
Abdominal discomfort	19.51	15.56	147	26498	250580	79467163
Quadriparesis	19.48	15.56	13	26632	3488	79714255
Pyrexia	19.39	15.56	140	26505	678569	79039174
Persistent depressive disorder	19.37	15.56	9	26636	1196	79716547
Hallucinations, mixed	19.28	15.56	17	26628	6882	79710861
Intentional product use issue	19.23	15.56	101	26544	152011	79565732
Pregnancy	18.96	15.56	33	26612	26818	79690925
Neuropathy peripheral	18.80	15.56	12	26633	141293	79576450
Intentional overdose	18.77	15.56	6	26639	105954	79611789
Anxiety	18.38	15.56	144	26501	248368	79469375
Lung disorder	18.38	15.56	64	26581	80493	79637250
Enthesopathy	18.35	15.56	21	26624	11587	79706156
Memory impairment	18.34	15.56	80	26565	111654	79606089
Axial spondyloarthritis	18.23	15.56	7	26638	579	79717164
Cardiac failure	18.19	15.56	15	26630	154827	79562916
Electrocardiogram QT prolonged	18.13	15.56	4	26641	90382	79627361
Amnesia	17.91	15.56	54	26591	63003	79654740
Constipation	17.73	15.56	43	26602	283007	79434736
Glaucoma	17.64	15.56	27	26618	19734	79698009
Ankylosing spondylitis	17.50	15.56	21	26624	12184	79705559
Skin reaction	17.31	15.56	24	26621	16044	79701699
Oxygen saturation decreased	17.11	15.56	11	26634	129036	79588707
Hepatic enzyme increased	17.09	15.56	112	26533	182498	79535245
Multiple fractures	17.08	15.56	17	26628	8009	79709734
Mast cell activation syndrome	16.84	15.56	7	26638	713	79717030
Eye disorder	16.83	15.56	29	26616	23383	79694360
Therapy non-responder	16.63	15.56	68	26577	92237	79625506
Asthma	16.60	15.56	89	26556	135006	79582737
Adrenoleukodystrophy	16.48	15.56	4	26641	68	79717675
Completed suicide	16.47	15.56	36	26609	245731	79472012
Infusion site rash	16.43	15.56	9	26636	1693	79716050
Peritoneal haematoma	16.38	15.56	5	26640	206	79717537
Breast cancer stage III	15.92	15.56	18	26627	9808	79707935

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AC01	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Oxicams
ATC	M02AA07	MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use
ATC	S01BC06	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:35544	cyclooxygenase inhibitors
CHEBI has role	CHEBI:35842	anti-rheumatic drugs
CHEBI has role	CHEBI:50630	COX-1 inhibitor
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Osteoarthritis	indication	396275006
Ankylosing spondylitis	off-label use	9631008	DOID:7147
Juvenile rheumatoid arthritis	off-label use	410795001
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Gastrointestinal perforation	contraindication	51875005
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Gastrointestinal hemorrhage	contraindication	74474003
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Acute hepatic failure	contraindication	197270009
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Drug-induced hepatitis	contraindication	235876009
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Thrombosis	contraindication	439127006
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.31	acidic
pKa2	8.26	acidic
pKa3	5.18	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	4.70	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	5.18	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_SHEEP		IC50	4.68	CHEMBL
Cyclooxygenase	Enzyme		PGH1_BOVIN PGH2_BOVIN		IC50	4.19	CHEMBL
Cyclooxygenase	Enzyme		PGH2_RAT PGH1_RAT		IC50	7	CHEMBL

External reference:

ID	Source
D00127	KEGG_DRUG
85056-47-9	SECONDARY_CAS_RN
4018626	VANDF
C0031990	UMLSCUI
CHEBI:8249	CHEBI
CHEMBL527	ChEMBL_ID
CHEMBL2106953	ChEMBL_ID
CHEMBL2108444	ChEMBL_ID
DB00554	DRUGBANK_ID
D010894	MESH_DESCRIPTOR_UI
C061072	MESH_SUPPLEMENTAL_RECORD_UI
54676228	PUBCHEM_CID
7273	IUPHAR_LIGAND_ID
3713	INN_ID
13T4O6VMAM	UNII
197288	RXNORM
1529	MMSL
1753	MMSL
5308	MMSL
d00343	MMSL
002389	NDDF
006310	NDDF
27754002	SNOMEDCT_US
387153005	SNOMEDCT_US
421574004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Feldene	HUMAN PRESCRIPTION DRUG LABEL	1	0069-3220	CAPSULE	10 mg	ORAL	NDA	29 sections
Feldene	HUMAN PRESCRIPTION DRUG LABEL	1	0069-3220	CAPSULE	10 mg	ORAL	NDA	29 sections
Feldene	HUMAN PRESCRIPTION DRUG LABEL	1	0069-3230	CAPSULE	20 mg	ORAL	NDA	29 sections
Feldene	HUMAN PRESCRIPTION DRUG LABEL	1	0069-3230	CAPSULE	20 mg	ORAL	NDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0756	CAPSULE	10 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0756	CAPSULE	10 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0757	CAPSULE	20 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0757	CAPSULE	20 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0143-3107	CAPSULE	10 mg	ORAL	ANDA	25 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	0143-3108	CAPSULE	20 mg	ORAL	ANDA	25 sections
PIROXICAM	HUMAN PRESCRIPTION DRUG LABEL	1	16590-187	CAPSULE	10 mg	ORAL	ANDA	29 sections
PIROXICAM	HUMAN PRESCRIPTION DRUG LABEL	1	16590-188	CAPSULE	20 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-285	CAPSULE	20 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-520	CAPSULE	10 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29033-012	CAPSULE	10 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29033-013	CAPSULE	20 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29300-255	CAPSULE	10 mg	ORAL	ANDA	20 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29300-255	CAPSULE	10 mg	ORAL	ANDA	20 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29300-256	CAPSULE	20 mg	ORAL	ANDA	20 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	29300-256	CAPSULE	20 mg	ORAL	ANDA	20 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42254-062	CAPSULE	20 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42254-143	CAPSULE	10 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42291-674	CAPSULE	10 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42291-674	CAPSULE	10 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42291-677	CAPSULE	20 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42291-677	CAPSULE	20 mg	ORAL	ANDA	28 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42543-114	CAPSULE	10 mg	ORAL	ANDA	29 sections
Piroxicam	HUMAN PRESCRIPTION DRUG LABEL	1	42543-115	CAPSULE	20 mg	ORAL	ANDA	29 sections
PIROXICAM	HUMAN PRESCRIPTION DRUG LABEL	1	42549-542	CAPSULE	20 mg	ORAL	ANDA	29 sections
PIROXICAM	HUMAN PRESCRIPTION DRUG LABEL	1	42571-176	CAPSULE	10 mg	ORAL	ANDA	28 sections